ClinicalTrials.gg
TerminatedNCT04400331Updated Nov 3, 2026

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

A Phase 3 interventional study of Valbenazine in Chorea, Huntington, sponsored by Neurocrine Biosciences. Terminated at 34 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2026.
Updated Nov 3, 2026Now TerminatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
21st of 90
154 · median 44
Started
2020
with 7 others
Phase 3
14 of 138
2 open now
Registered
96th of 138
by date

Among the 138 studies in Huntington Disease with a site in United States, this one is the 21st largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2020, is one of 14 in phase 3, and was the 96th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Read the detailed description

After completion of Week 156/early termination visit, participants in the US will be given the option to continue into an extended maintenance period for up to 104 weeks and participants in Canada will have the option to participate in a separate open-label study (Study NBI-98854-HD3022).

03

Conditions studied

  • Chorea, Huntington

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Either #1 or #2 must be met for inclusion eligibility.

  1. Have participated in Study NBI-98854-HD3005 and

    a. Study drug dosing completion of Study NBI-98854-HD3005, as demonstrated by completed study drug dosing through the follow-up visit or early terminated Study NBI-98854-HD3005 for administrative reasons due to COVID-19 (for example, site closure related to COVID-19)

  2. Did not participate in Study NBI-98854-HD3005 and

    1. Have a clinical and genetic diagnosis of Huntington Disease (HD) with chorea
    2. Be able to walk, with or without the assistance of a person or device
  3. Be able to read and understand English and capable of providing consent to study participation or have a legally authorized representative providing consent and the participant providing assent
  4. Participants of must agree to use consistently while participating in the study until 30 days after last dose of the study treatment

Exclusion criteria

Exclusion Criteria:

  1. Have difficulty swallowing
  2. Are currently pregnant or breastfeeding
  3. Have a known history of long syndrome, cardiac tachyarrhythmia, left bundle-branch block, atrioventricular (AV) block, uncontrolled bradyarrhythmia, or heart failure
  4. Have an unstable or serious medical or psychiatric illness
  5. Have a significant risk of suicidal behavior
  6. Have a history of substance dependence or substance (drug) or alcohol abuse, within 1 year of screening
  7. Have received gene therapy at any time
  8. Have received an drug in a clinical study (other than valbenazine) within 30 days before the baseline visit or plan to use such investigational drug (other than valbenazine) during the study
  9. Have had a blood loss ≥550 mL or donated blood within 30 days before the baseline visit
  10. Have a history of severe hepatic impairment or history of protocol specified hematologic abnormalities during the course of the NBI-98854-HD3005 study
  11. Had a medically significant illness within 30 days before baseline, or any history of neuroleptic malignant syndrome
  12. Have a known to any component of the formulation of valbenazine
  13. For participants who did not participate in NBI-98854-HD3005: have a history of VMAT2 inhibitor use within 30 days of baseline
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Capsule, administered orally once daily.

    Drug: Valbenazine

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: NBI-98854

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 262 weeks

Secondary outcomes

  1. Change from Baseline in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score

    The TMC is part of the motor assessment of the UHDRS and measures chorea in 7 different body parts including the face, oral-buccal-lingual region, trunk and each limb independently. The TMC score is the sum of the individual scores and ranges from 0 to 28. A decrease in score indicates improvement in chorea.

    Time frame: Up to 262 weeks

07

Study locations

34 sites
  • Neurocrine Clinical Site
    Birmingham, Alabama 35294, United States
  • Neurocrine Clinical Site
    Little Rock, Arkansas 72205, United States
  • Neurocrine Clinical Site
    La Jolla, California 92037, United States
  • Neurocrine Clinical Site
    Aurora, Colorado 80045, United States
  • Neurocrine Clinical Site
    Washington D.C., District of Columbia 20007, United States
  • Neurocrine Clinical Site
    Boca Raton, Florida 33486, United States
  • Neurocrine Clinical Site
    Gainesville, Florida 32608, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30329, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60611, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60612, United States
  • Neurocrine Clinical Site
    Indianapolis, Indiana 46202, United States
  • Neurocrine Clinical Site
    Iowa City, Iowa 52242, United States
  • Neurocrine Clinical Site
    Wichita, Kansas 67226, United States
  • Neurocrine Clinical Site
    Louisville, Kentucky 40202, United States
  • Neurocrine Clinical Site
    New Orleans, Louisiana 70121, United States
  • Neurocrine Clinical Site
    Boston, Massachusetts 02215, United States
  • Neurocrine Clinical Site
    Charlestown, Massachusetts 02129, United States
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48105, United States
  • Neurocrine Clinical Site
    Omaha, Nebraska 68105, United States
  • Neurocrine Clinical Site
    Rochester, New York 14618, United States
  • Neurocrine Clinical Site
    Williamsville, New York 14221, United States
  • Neurocrine Clinical Site
    Durham, North Carolina 27705, United States
  • Neurocrine Clinical Site
    Columbus, Ohio 43221, United States
  • Neurocrine Clinical Site
    Toledo, Ohio 43614, United States
  • Neurocrine Clinical Site
    Pittsburgh, Pennsylvania 15213, United States
  • Neurocrine Clinical Site
    Charleston, South Carolina 29425, United States
  • Neurocrine Clinical Site
    Columbia, South Carolina 29203, United States
  • Neurocrine Clinical Site
    Greenville, South Carolina 29615, United States
  • Neurocrine Clinical Site
    Nashville, Tennessee 37212, United States
  • Neurocrine Clinical Site
    Houston, Texas 77054, United States
  • Neurocrine Clinical Site
    Burlington, Vermont 05401, United States
  • Neurocrine Clinical Site
    Vancouver, British Columbia V6T 2B5, Canada
  • Neurocrine Clinical Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Neurocrine Clinical Site
    Toronto, Ontario MK2 1E1, Canada
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2025, 61 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
May 22, 2020
StartActual
Sep 18, 2020
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 5, 2025
Results delay requested
Oct 30, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Sponsor Decision
changed Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Completed→Terminated
    Why stopped Sponsor Decision
    + 3 other changes: verification date, registry dates and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04400331
Collaborators
Huntington Study Group
Responsible party
Sponsor
First posted
May 22, 2020
Start date
Sep 18, 2020
Primary completion
Nov 5, 2025
Completion
Nov 5, 2025
Last update
Nov 3, 2026

Study contacts

Chief Medical Officer
study director · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion